Endo International slumps on dour Q2 forecast
06/05/2022 14:04
** Drugmaker's shares ENDP.O fall 35.2% to $1.31 in heavy
premarket trading
** Co forecasts Q2 sales of $500 - $525 mln, below Refinitiv
IBES estimates of $655.6 mln, hurt by competition for co's blood
pressure drug Vasostrict urn:newsml:reuters.com:*:nPresQdQPa
** "As we manage through the Vasostrict loss of exclusivity
over the near term, we remain focused on investing to advance
our product portfolio for the long term" - CEO Blaise Coleman
** ENDP shares have lost nearly half their value YTD
(Reporting by Manas Mishra)
((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15; within U.S. +1 646 223 8780;))
Recent news on Endo International
See all newsBrief: Endo International PLC Files For Offering Of Up To 31.1 Million Common Shares By The Selling Stockholders - SEC Filing
Brief: Par Pharmaceutical Issues Voluntary Nationwide Recall Of Seven Lots Of Treprostinil Injection
Brief: Endo International Says Wholly-Owned Subsidiary Endo Finance Priced Its $1.5 Bln Senior Secured Seven-Year Term Loan
Brief: Endo, Inc. Announces Pricing Of $1 Bln Of Senior Secured Notes
Brief: Endo Announces Proposed Private Offering Of Senior Secured Notes